Deepti A. Singh, MD

Clinical Associate of Medicine

Dr. Deepti Singh is a hematology and oncology specialist. She has expertise treating gastrointestinal cancers, including colorectal, gallbladder, liver, and stomach cancers. Dr. Singh also has a special interest in treating blood disorders, such as coagulation and thrombosis.

An active researcher, Dr. Singh is conducting clinical trials of therapies for colorectal cancer and stomach cancer. In addition to her patient care and research activities, Dr. Singh serves as an educator for the University of Chicago Pritzker School of Medicine, where she shares her knowledge of hematology/oncology with medical students, residents, and fellows.

Practice Locations

Center for Advanced Medicine
5758 S. Maryland Avenue
Chicago, IL 60637

University of Chicago Medical Center
5841 S. Maryland Avenue
Chicago, IL 60637

Year Started Practice

1999

Board Certifications

Hematology
Internal Medicine
Oncology

Medical School

Northeastern Ohio Universities College of Medicine, Rootstown

Internship and Residency

Akron City Hospital, Akron, OH

Fellowships

University Hospitals of Cleveland/Ireland Cancer Center
Case Western Reserve University, Cleveland, OH

Memberships

American Society of Clinical Oncology
American Society of Hematology

Languages Spoken

English
Hindi

Email

dsingh@medicine.bsd.uchicago.edu

Office Phone

(773) 702-6149

Office Fax

(773) 702-3163

Office Postal Address

Deepti A. Singh, MD
University of Chicago Medical Center
5841 S. Maryland Avenue, MC 2115
Chicago, IL 60637

Clinical Interests

• Hematology/oncology
• Anemia
• Coagulation disorders
• Colon cancer
• Gallbladder cancer
• Liver cancer
• Stomach cancer
• Thrombosis

Request an appointment online
or call HealthLink at
1-888-UCH-0200

Selected Publications

Singh DA, Kindler HL, Eng C, Skoog, L, Lenz HJ, Taber D, Vokes EE. Phase II trial of the Epothilone B analog BMS-247550 in patients (pts) with hepatobiliary cancer. Proc Am Soc Clin Oncol. 22:281. 2003. (abstr 1127)

Kindler HL, Friberg G, Stadler WM, Singh D, Locker G, Nattam S, Kozloff M, Dachman A, Vokes EE. Bevacizumab plus Gemcitabine is an active combination in patients with advanced pancreatic cancer: Interim results of an ongoing phase II trial from the University of Chicago Phase II Consortium. Gastrointestinal Cancers Symposium. 2004 (abstr 68).